As filed with the Securities and Exchange Commission on August 12, 2022

Registration No. 333-[•]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

POINT BIOPHARMA GLOBAL INC.

(Exact name of registrant as specified in its charter)

Delaware	85-0800493
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

4850 West 78th Street,

Indianapolis, IN, 46268

(Address of Principal Executive Offices and Zip)

Point Biopharma Global Inc. 2021 Equity Incentive Plan (the "2021 Plan")

(Full Title of the Plans)

Bill Demers

4850 West 78th Street,

Indianapolis, IN

(647) 812-2417

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Susan V. Sidwell, Esq.

Bass Berry & Sims, PLC

150 Third Avenue South

Suite 2800

Nashville, Tennessee 37201

Tel: (615) 742-6200

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐			Accelerated filer		☐
Non-accelerated filer		☒			Smaller reporting company		☒
			Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8 registers 3,604,871 additional shares of common stock, par value $0.0001 per share ("Common Stock"), of POINT Biopharma Global Inc. (the "Registrant") under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the "Plan") as a result of the provision in the Plan providing for an automatic annual increase in the number of shares of Common Stock reserved and available for issuance under the Plan on each January 1, beginning in 2022, by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares of Common Stock as determined by the Registrant's Board of Directors. Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 3,604,871. The Registrant previously registered shares of Common Stock under the Plan on a Registration Statement on Form S-8 (File No. 333-259171) (the "Prior Registration Statement") filed with the Securities and Exchange Commission (the "Commission") on August 30, 2021.

The information contained in the Registrant's Prior Registration Statement is hereby incorporated by reference pursuant to General Instruction E, except for Item 8. Exhibits of Part II.

Part II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

EXHIBIT INDEX

Exhibit No.		Description
3.1		Amended and Restated Certificate of Incorporation of POINT Biopharma Global Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company on July 1, 2021).
3.2		Amended and Restated Bylaws of POINT Biopharma Global Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed by the Company on July 1, 2021).
5.1*		Opinion of Bass, Berry & Sims PLC.
23.1*		Consent of Bass, Berry & Sims PLC (included in Exhibit 5.1)
23.2*		Consent of Armanino LLP (Auditor)
24.1*		Power of Attorney (included on signature page).
99.1		POINT Biopharma Global Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by the company July 1, 2021).
99.2	Form of Non-Qualified Stock Option Agreement Under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (incorporated by reference to Exhibit 10.4 to the Form 8-K filed by the Company July 1, 2021).
99.3	Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Non-Employee Directors) (incorporated by reference to Exhibit 10.5 to the Form 8-K filed by the Company July 1, 2021).
99.4	Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (incorporated by reference to Exhibit 10.6 to the Form 8-K filed by the Company July 1, 2021).
99.5	Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Non-Employee Directors) (incorporated by reference to Exhibit 10.7 to the Form 8-K filed by the Company July 1, 2021).
99.6	Form of Incentive Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to Form 8-K filed by the Company July 1, 2021).
107.1*		Filing Fee Table

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, on August 12, 2022.

POINT BIOPHARMA GLOBAL INC.
By:	/s/ Bill Demers
Bill Demers
Chief Financial Officer

POWER OF ATTORNEY AND SIGNATURES

Each person whose signature appears below constitutes and appoints each of Joe McCann, and Bill Demers, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dated indicated.

Name		Title		Date
/s/ Joe McCann		Chief Executive Officer (Principal Executive Officer) and Director		August 12, 2022
Dr. Joe McCann, Ph.D.
/s/ Allan C. Silber		Executive Chair and Director		August 12, 2022
Allan C. Silber
/s/ Bill Demers		Chief Financial Officer (Principal Financial and Accounting Officer)		August 12, 2022
Bill Demers
/s/ Neil Fleshner		Chief Medical Officer and Director		August 12, 2022
Dr. Neil Fleshner
/s/ Rajesh K. Malik		Director		August 12, 2022
Dr. Rajesh K. Malik, M.D.
/s/ Jonathan Ross Goodman		Director		August 12, 2022
Jonathan Ross Goodman
/s/ Gerald Hogue		Director		August 12, 2022
Gerald Hogue
/s/ David C. Lubner		Director		August 12, 2022
David C. Lubner
/s/ Yael Margolin		Director		August 12, 2022
Dr. Yael Margolin, Ph.D.